Early observations and pilot data that first suggested a new direction
Invasive fungal infections (IFI) have been a leading cause of infectious mortality in immunocompromised patients, particularly those with prolonged neutropenia from AML chemotherapy or hematopoietic stem cell transplantation (HSCT). Invasive aspergillosis alone carries mortality rates of 30-60% despite treatment. The traditional approach of empiric amphotericin B for persistent febrile neutropenia was toxic and imprecise. The introduction of fluconazole prophylaxis in the 1990s significantly reduced invasive candidiasis in HSCT recipients, as demonstrated by the landmark Goodman 1992 study showing 3% vs 16% reduction in systemic fungal infections. However, fluconazole has no activity against Aspergillus species, leaving patients vulnerable to the most lethal fungal pathogen.
Landmark RCTs and pivotal trials that established the evidence base
The paradigm-shifting Cornely 2007 study randomized 602 patients with AML or MDS receiving remission-induction chemotherapy to posaconazole vs fluconazole or itraconazole prophylaxis. Posaconazole significantly reduced invasive aspergillosis (2% vs 7%), proven or probable IFI (5% vs 9%), and overall survival was improved (hazard ratio 0.73). This was the first prophylactic antifungal to demonstrate a survival benefit in this population. The Ullmann 2007 companion study in allogeneic HSCT recipients with graft-versus-host disease showed similar benefits. These trials established mold-active azole prophylaxis as the new standard, fundamentally changing the approach from reactive empiric treatment to proactive prevention of the most dangerous fungal infections.
Follow-up studies, subgroup analyses, and real-world validation
Isavuconazole emerged as an alternative mold-active azole with a more favorable drug interaction profile and no QTc prolongation, unlike voriconazole. The SECURE trial established non-inferiority of isavuconazole to voriconazole for treatment of invasive aspergillosis, and it was subsequently studied as a prophylactic agent. Posaconazole delayed-release tablets replaced the oral suspension, achieving more reliable therapeutic drug levels and simplifying prophylaxis delivery. Voriconazole prophylaxis also proved effective in certain high-risk populations. The diagnostic-driven approach gained momentum, using galactomannan screening and CT imaging to guide pre-emptive rather than empiric antifungal therapy, potentially reducing unnecessary antifungal exposure in lower-risk patients.
Integration into clinical practice guidelines and recommendations
IDSA, ECIL, and ASBMT guidelines now recommend mold-active azole prophylaxis for high-risk immunocompromised patients. For AML/MDS during induction chemotherapy, posaconazole is the preferred agent based on the demonstrated survival benefit. For allogeneic HSCT recipients, particularly those with GVHD, posaconazole or voriconazole prophylaxis is recommended. Fluconazole remains acceptable for lower-risk populations (autologous HSCT, non-myeloablative conditioning). The ECIL guidelines have introduced risk stratification to guide prophylaxis intensity, recognizing that not all immunocompromised patients require mold-active agents.
IDSA Aspergillosis Guidelines
Posaconazole prophylaxis recommended for patients with AML/MDS during remission-induction chemotherapy and allogeneic HSCT recipients with GVHD
ECIL-6 Antifungal Prophylaxis Guidelines
Posaconazole (AI evidence) for AML induction; posaconazole or voriconazole for allogeneic HSCT with GVHD; fluconazole acceptable for lower-risk HSCT
Now
Current standard of care and ongoing research directions
Mold-active prophylaxis has substantially reduced invasive aspergillosis incidence in high-risk patients, but emerging challenges include breakthrough infections with azole-resistant Aspergillus species (particularly in regions with environmental azole use in agriculture) and non-Aspergillus molds like Mucorales. The novel antifungal pipeline offers hope: olorofim (an orotomide targeting dihydroorotate dehydrogenase), fosmanogepix (targeting Gwt1), and rezafungin (a long-acting echinocandin enabling once-weekly dosing) represent new mechanisms of action. Ibrexafungerp, the first oral glucan synthase inhibitor, has expanded treatment options. Research continues on biomarker-guided prophylaxis strategies, therapeutic drug monitoring optimization, and combination prophylaxis approaches for the highest-risk patients.
Why is fluconazole insufficient for high-risk neutropenic patients?+
Fluconazole effectively prevents invasive candidiasis but has no activity against Aspergillus species or other molds. In patients with prolonged neutropenia (AML induction, allogeneic HSCT), invasive aspergillosis is the predominant fungal threat with 30-60% mortality. Mold-active azoles like posaconazole provide broader coverage and have demonstrated survival benefit over fluconazole in this population.
Which patients need mold-active prophylaxis vs fluconazole?+
Mold-active prophylaxis (posaconazole, voriconazole) is recommended for: AML/MDS during induction chemotherapy, allogeneic HSCT recipients with GVHD on immunosuppression, and patients with prolonged neutropenia (>10 days). Fluconazole is acceptable for lower-risk populations: autologous HSCT, non-myeloablative allogeneic HSCT without GVHD, and solid organ transplant recipients.
What is the concern about azole-resistant Aspergillus?+
Azole-resistant Aspergillus fumigatus, driven partly by agricultural fungicide use (same triazole class), has reached prevalence rates of 5-30% in parts of Europe. These infections have mortality rates exceeding 80% in immunocompromised patients. Environmental surveillance, therapeutic drug monitoring, and susceptibility testing of clinical isolates are increasingly important. Novel antifungals with non-azole mechanisms (olorofim, fosmanogepix) are being developed partly to address this threat.
